A5007909131- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Lipoproteins and Cardiovascular Health
- Diabetes Management and Research
- Adipokines, Inflammation, and Metabolic Diseases
- Diet and metabolism studies
- Obstructive Sleep Apnea Research
- Peripheral Artery Disease Management
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Adipose Tissue and Metabolism
- Cardiac, Anesthesia and Surgical Outcomes
- Aortic aneurysm repair treatments
- Diabetic Foot Ulcer Assessment and Management
- Nutrition, Genetics, and Disease
- Drug Transport and Resistance Mechanisms
- Liver Disease Diagnosis and Treatment
- Genetic Associations and Epidemiology
- Systemic Sclerosis and Related Diseases
- Chronic Kidney Disease and Diabetes
- Cerebrovascular and Carotid Artery Diseases
- Neuroscience of respiration and sleep
- Cardiovascular Function and Risk Factors
- Pharmacogenetics and Drug Metabolism
University of Pavol Jozef Šafárik
2014-2024
Univerzitná Nemocnica Louisa Pasteura
2006-2024
Ocná klinika
1992-1999
Toronto General Hospital
1997-1998
University of Toronto
1997-1998
Technical University of Košice
1992
University of Veterinary Medicine in Košice
1990-1991
Pharmacogenetic studies revealed that variants in genes related to the pharmacokinetics of metformin were associated with glucose‐lowering effect metformin. The aim this study was investigate possible associations encoding organic cationic transporters–solute carrier family 22, members A1, A2 ( SLC22A1 , SLC22A2 ) and solute 47, member A1 SLC47A1 response type 2 diabetes. One hundred forty‐eight drug‐naive patients diabetes included study. Genotyping for rs622342, rs316019 rs2289669...
The aim of the present study was to analyse effects sulphonylurea treatment on parameters glycaemic control in relation transcription factor 7-like 2 (TCF7L2) genotypes. In 87 patients with type diabetes who failed achieve metformin monotherapy, 6-month addition reductions haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels were evaluated. Reduction HbA1c FPG response significantly higher CC genotype compared those CT+TT (1.16 ± 0.07 vs. 0.86 0.07%, p = 0.003; 1.57 0.12 1.14 0.14...
Abstract The presence or absence of coronary artery disease (CAD) in diabetic patients has been related to the level circulating plasma lipoproteins. This study examines whether there is a relationship between actual severity CAD and concentration major classes lipoproteins (HDL, LDL, triglyceride-rich (TRL), their Sf 12 60 400 subfractions), particularly numbers lipoprotein particles, men women with type 2 diabetes. 174 (136 men, 38 women) who underwent angiography were studied. Nine...
Gliptins act by increasing endogenous incretin levels. Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide (GIPR) are their indirect drug targets. Variants of GLP1R GIPR have previously been associated with the effect. The aim present pilot study was to examine associations gene variants glycaemic response gliptins. A total 140 consecutive patients type 2 diabetes were followed-up 6 months after initiation gliptin treatment. rs6923761 (Gly168Ser) rs10423928...
OBJECTIVE The aim of the present study was to examine risk factors for electrophysiologic severity diabetic peripheral sensorimotor polyneuropathy (DSP). RESEARCH DESIGN AND METHODS A total 97 patients with type 1 diabetes (25 patients) or 2 (72 were included in this cross-sectional study. Nerve conduction studies (NCS) performed on median motor and sensory nerves, peroneal nerve, both sural nerves. DSP expressed as sum nerve velocities (SNCV) score distal amplitudes (SAMP) above-mentioned...
Background:We aimed to analyse quantitative effects of treatment with sulphonylurea in addition metformin on parameters glycemic control relation KCNQ1 genotypes, and identify factors predictive for the response treatment.Material/Methods:Effect 6-month therapy according genotypes was evaluated 87 patients type 2 diabetes who failed achieve monotherapy. rs163184 (T>G) polymorphism determined by real-time PCR melting analysis unlabeled probe.Results:The reduction fasting plasma glucose (ΔFPG)...
Previous studies showed associations between variants in TCF7L2 gene and the therapeutic response to sulfonylureas. All sulfonylureas stimulate insulin secretion by closure of ATP-sensitive potassium (KATP) channel. The aim present study was compare genotype specific effect gliclazide binding KATP channel A-site (Group 1) with AB-site 2). A total 101 patients were treated for 6 months as an add-on therapy previous metformin treatment. rs7903146 C/T identified real-time PCR subsequent melting...
Objective(s) High variability in clinical response to metformin is often observed type 2 diabetes (T2D) patients, and it highlights the need for identification of genetic components affecting efficiency therapy. Aim this observational study evaluate role tagSNPs (tagging single nucleotide polymorphisms) from genomic regions coding six transporter genes with respect short-term efficiency. Design 102 6 transporters were genotyped group T2D patients treated 3 months. Methods Most significant...
Potential links between metabolic derangements and adipose tissue (AT) inflammation in patients with chronic obstructive pulmonary disease (COPD) are unexplored. We investigated AT expressions of interleukin (IL)-6, tumor necrosis factor (TNF)-α, CD68 (macrophage cell surface receptor), caspase-3, Bax, their relationships to the phenotype nine cachectic, 12 normal-weight, overweight, 11 obese COPD (age<mml:math...
<i>Background:</i> CD40, a transmembrane receptor of the tumor necrosis factor gene superfamily, is activated in response to cellular stress, including hypoxia, and orchestrates process inflammation via secondary messengers such as mitogen-activated protein kinase 4 (MKK4) c-Jun NH<sub>2</sub>-terminal kinases (JNK). <i>Objectives:</i> We hypothesized that MKK4 JNK expression increased adipose tissue patients with very severe chronic obstructive pulmonary...
Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment DPP4 inhibitors. Patients & methods: 206 patients type 2 diabetes (116 men and 90 women) were treated sitagliptin or vildagliptin (both 100 mg/day) in combination metformin metformin/sulphonylurea over months, the reduction glycated hemoglobin (HbA1c) was measured. Results: Rs6923761 GLP1R significantly associated a HbA1c (adjusted p = 0.006). Homozygotes for minor A allele...
The aim of the present pilot pharmacogenetic study was to analyse quantitative effects sulphonylurea treatment in addition metformin on parameters glycemic control with respect CDKAL1 genotypes patients type 2 diabetes. Effect 6-month therapy according evaluated 101 diabetes who failed achieve monotherapy. rs7756992 polymorphism determined by melting curve analysis small amplicon following real-time PCR. After fasting plasma glucose (FPG) levels were significantly different (p=0.045) among...
Dyslipidemia in the metabolic syndrome (MS) is considered to be one of most important risk factors for atherosclerosis. It characterized by hypertriglyceridemia, low concentration plasma HDL-cholesterol, predominance small dense LDL particles and an increased apolipoprotein B (apoB). The pathogenesis this type dyslipidemia partially explained, but its genetic background still unknown. To evaluate influence cholesterol ester transfer protein (CETP) TaqIB polymorphism, lipoprotein lipase (LPL)...